Immunotherapy Archives - Cancer Therapy Advisor

General Oncology

Checklist Ensures Adherence to Recommended CAR-T Cell Administration Processes

By

Joyce Pagan

April 19, 2019

How one facility ensures compliance with a complex treatment protocol.

Some chemotherapeutic drugs have been shown to stimulate the immune system, despite the historical belief that chemotherapies are immunosuppressive.

General Oncology

Chemotherapy-Stimulated Immune Response: An Open Debate

By

Jonathan Goodman, MPhil

April 4, 2019

Some chemotherapeutic drugs have been shown to stimulate the immune system, despite the historical belief that chemotherapies are immunosuppressive.

An analysis by members of the FDA showed that time to treatment discontinuation may be a viable end point to assess drug efficacy in the postmarketing setting.

AACR 2019

The Predictive Ability of a Cancer Subtype Ontology Assignment

By

Susan Moench, PhD, PA-C

April 3, 2019

The Cancer Subtype Ontology resource includes 840 different cancer subtypes, many of which are novel.

Clinicians continue to learn about which patients will benefit most from different immunotherapy tre

AACR 2019

Novel Toxicities, Anticancer Activity of Anti-CD22 CAR-T Therapies Revealed

By

Susan Moench, PhD, PA-C

April 2, 2019

Hemophagocytic lymphohistiocytosis is a rare, but potentially fatal, complication of immunotherapy, resulting from immune hyperactivation.

Most invasive breast cancers present as adenocarcinomas and are classified based on microscopic appearance. The most common histologic types of invasive breast cancer are ductal and lobular carcinomas, accounting for approximately 75% and 15% of all cases in the US, respectively.3

AACR 2019

High Baseline Inflammatory Biomarker Levels Linked to Shorter OS in mTNBC

By

Susan Moench, PhD, PA-C

April 1, 2019

On multivariate analyses, high baseline levels of IL-6 and CRP, but not IL-8, were associated with shorter OS in patients with breast cancer receiving atezolizumab.

It is unclear whether breast cancer screening — and specifically mammography — reduces the likelihoo

AACR 2019

Immune Biomarkers as Predictors of Response to Checkpoint Blockade in Breast Cancer

By

Susan Moench, PhD, PA-C

April 1, 2019

Results from this study showed that a close spatial distribution between CD3-positive T cells and cancer cells was a biomarker for response to pembrolizumab.

Current and Emerging Cervical Cancer Screening Guidelines and Tools

AACR 2019

Chemoimmunotherapy Confers Survival Benefit in Patients With HPV16-Induced Cervical Cancer

By

Susan Moench, PhD, PA-C

April 1, 2019

Coadministration of the HPV16-specific vaccine, ISA101, with chemotherapy was found to be associated with stronger tumor immunity.

In a Canadian matched cohort study, intolerance drove patients with CP-CML to switch from generic im

Lung Cancer

Immunotherapy Followed by Osimertinib: Increased Risk of Severe Immune-Related AEs

By

Susan Moench, PhD, PA-C

March 26, 2019

In this study, no patients receiving sequential administration of an immune checkpoint inhibitor followed by erlotinib developed a severe immune-related AE.